Neurocognitive Adverse Events in Patients With ALK or ROS1-Positive, Advanced or Metastatic NSCLC Receiving Lorlatinib. Zhao B, Wu J, Ma W. J Thorac Oncol 2023;18:e26-e27.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhao B, Wu J, Ma W. Neurocognitive Adverse Events in Patients With ALK or ROS1-Positive, Advanced or Metastatic NSCLC Receiving Lorlatinib. J Thorac Oncol 2023;18:e26-e27.
PMID: 36842815